These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 21950636)

  • 1. The structure and function of the glucagon-like peptide-1 receptor and its ligands.
    Donnelly D
    Br J Pharmacol; 2012 May; 166(1):27-41. PubMed ID: 21950636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of action of glucagon-like peptide 1 in the pancreas.
    Doyle ME; Egan JM
    Pharmacol Ther; 2007 Mar; 113(3):546-93. PubMed ID: 17306374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
    Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
    Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain.
    Runge S; Schimmer S; Oschmann J; Schiødt CB; Knudsen SM; Jeppesen CB; Madsen K; Lau J; Thøgersen H; Rudolph R
    Biochemistry; 2007 May; 46(19):5830-40. PubMed ID: 17444618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrination of a GLP-1 Receptor Agonist for Glycemic Control without Emesis.
    Borner T; Workinger JL; Tinsley IC; Fortin SM; Stein LM; Chepurny OG; Holz GG; Wierzba AJ; Gryko D; Nexø E; Shaulson ED; Bamezai A; Da Silva VAR; De Jonghe BC; Hayes MR; Doyle RP
    Cell Rep; 2020 Jun; 31(11):107768. PubMed ID: 32553160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of glucose homeostasis by GLP-1.
    Nadkarni P; Chepurny OG; Holz GG
    Prog Mol Biol Transl Sci; 2014; 121():23-65. PubMed ID: 24373234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
    West GM; Willard FS; Sloop KW; Showalter AD; Pascal BD; Griffin PR
    PLoS One; 2014; 9(9):e105683. PubMed ID: 25180755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 (GLP-1).
    Müller TD; Finan B; Bloom SR; D'Alessio D; Drucker DJ; Flatt PR; Fritsche A; Gribble F; Grill HJ; Habener JF; Holst JJ; Langhans W; Meier JJ; Nauck MA; Perez-Tilve D; Pocai A; Reimann F; Sandoval DA; Schwartz TW; Seeley RJ; Stemmer K; Tang-Christensen M; Woods SC; DiMarchi RD; Tschöp MH
    Mol Metab; 2019 Dec; 30():72-130. PubMed ID: 31767182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor.
    Li N; Lu J; Willars GB
    PLoS One; 2012; 7(10):e47936. PubMed ID: 23094100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minireview: Signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery.
    Koole C; Savage EE; Christopoulos A; Miller LJ; Sexton PM; Wootten D
    Mol Endocrinol; 2013 Aug; 27(8):1234-44. PubMed ID: 23864649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
    Runge S; Thøgersen H; Madsen K; Lau J; Rudolph R
    J Biol Chem; 2008 Apr; 283(17):11340-7. PubMed ID: 18287102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
    Maida A; Lovshin JA; Baggio LL; Drucker DJ
    Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.
    Jun LS; Showalter AD; Ali N; Dai F; Ma W; Coskun T; Ficorilli JV; Wheeler MB; Michael MD; Sloop KW
    PLoS One; 2014; 9(4):e93746. PubMed ID: 24695667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.